- PLN212.92m
- PLN295.83m
- PLN42.01m
Brief: Synthaverse Gets 45 Mln Zloty Loan From Polish Agency For Enterprise Development For Debt Refinancing
Brief: Synthaverse Receives Registration Certificate For Onko BCG Product In Paraguay Under Partnership With Blau
Brief: Synthaverse H1 Net Loss At 6.4 Mln Zlotys
Brief: Synthaverse Gets Poland's GIF Decision Extending Manufacturing For New Immunological Products Facility
Brief: Synthaverse Signs Annex to Extend CoraPharm Cooperation Deal Into New Markets
Brief: Synthaverse Receives Saudi Arabia Import Permit For BCG10 Vaccine
Brief: Synthaverse Appoints Dariusz Kucowicz As CFO
Brief: Synthaverse Signs Annex To Deal With Biodrug To Expand Onko BCG 100 Distribution To Australia And New Zealand
Brief: Synthaverse To End Distribution Agreement With Valentis In Turkey
Brief: Synthaverse Signed A Deal With Vivanta To Register, Deliver And Distribute Company's Product Onko
Brief: Synthaverse Q1 Net Loss 3.6 Million Zlotys
Brief: Synthaverse Receives Marketing Authorization For Onko BCG Medicinal Product In Ecuador
Brief: Synthaverse Gets Marketing Authorization For Onko BCG In Serbia
Brief: Synthaverse FY Net Loss 19.9 Million Zlotys
Brief: Synthaverse Appoints Artur Chodkowski As CEO
Brief: Synthaverse Q3 Net Loss 7.7 Million Zlotys
Brief: Synthaverse Receives Marketing Authorization For Onko BCG Drug In The Netherlands
Brief: Synthaverse H1 Net Loss At 5.3 Mln Zlotys
Brief: Synthaverse Signs Deal With Blau Farmaceutica For BCG 10 Vaccine